Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs for serious ocular and rare diseases. Adverum is evaluating its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of its lead indication, wet age-related macular degeneration. For more information, please visit www.adverum.com.
Employees: 51-200
Founded date: 2012
Investors 1
| Date | Name | Website |
| - | Avoro Capi... | avorocapit... |
Mentions in press and media 1
| Date | Title | Description | Source |
| 05.02.2024 | Adverum Biotechnologies Announces $127.5 Million Private Pla... | - | globenewsw... |